[March 31, 2014]

Bovie Medical Names Jack McCarthy Chief Commercialization Officer

Bovie Medical (NYSE MKT:BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today the appointment of Jack McCarthy, 47, as Chief Commercialization Officer.

Mr. McCarthy has 23 years of sales and marketing experience of which the last 16 years has been spent in the healthcare industry. Most recently, he served as Vice President of Sales and Marketing for US Healthcare at Z-Medica. Prior to that, Mr. McCarthy spent 15 years with Covidien (NYSE:COV), in positions of increasing responsibility where he was charged with achieving sales and business development goals. His most recent position at Covidien was as Area Sales Vice President for the Endo Mechanical Intelligent Device franchise, where he managed a team of 50 sales professionals. Mr. McCarthy is a graduate of Loyola College in Baltimore, Maryland, where he obtained a BA degree in Marketing in 1988 and an MBA in Marketing in 1990.

Robert L. Gershon, CEO, stated, "I am very pleased that we have been able to attract Jack McCarthy, a seasoned sales and business development executive to serve as our Chief Commercialization Officer. I have worked closely with Jack for nearly 10 years and have witnessed first-hand his ability to successfully launch innovative medical devices. Bovie is a well-respected brand in the medical community and it is our expectation that Jack, together with our existing managers, will further leverage the Bovie brand as well as accelerate the growth of J-Plasma®."

Mr. McCarthy entered into an employment agreement with the Company and was awarded a non-qualified stock option to purchase an aggregate of 213,000 shares of Bovie common stock, exercisable t the closing price on the effective date of his employment agreement. The option shall vest and be exercisable in four equal annual installments of 53,250 shares each, beginning on the first anniversary of the effective date.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product. J-Plasma® utilizes a gas ionization process that produces a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company's own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie Medical Corporation's website www.boviemed.com.

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Form 10-K for the year ended December 31, 2013. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie's website www.boviemed.com.

[ Back To TMCnet.com's Homepage ]